These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1527584)

  • 1. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
    Crawley JN
    J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
    Crawley JN
    Synapse; 1989; 3(4):346-55. PubMed ID: 2740993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry.
    Reum T; Schäfer U; Marsden CA; Fink H; Morgenstern R
    Neuropeptides; 1997 Feb; 31(1):82-8. PubMed ID: 9574843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens.
    Crawley JN
    Brain Res; 1988 Nov; 473(2):398-400. PubMed ID: 3233498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
    O'Neill MF; Dourish CT; Iversen SD
    Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites.
    Léna I; Roques BP; Durieux C
    J Neurochem; 1997 Jan; 68(1):162-8. PubMed ID: 8978722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
    Boyle SJ; Tang KW; Woodruff GN; McKnight AT
    Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms.
    Marshall FH; Barnes S; Hughes J; Woodruff GN; Hunter JC
    J Neurochem; 1991 Mar; 56(3):917-22. PubMed ID: 1993898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
    Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor.
    Pu SF; Zhuang HX; Han JS
    Brain Res; 1994 Sep; 657(1-2):159-64. PubMed ID: 7820614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulatory role for CCK-B antagonists in Parkinson's disease.
    Boyce S; Rupniak NM; Tye S; Steventon MJ; Iversen SD
    Clin Neuropharmacol; 1990 Aug; 13(4):339-47. PubMed ID: 1976438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure.
    Wunderlich GR; Rotzinger S; Bush DE; DeSousa NJ; Vaccarino FJ
    Brain Res; 2004 Mar; 1001(1-2):95-107. PubMed ID: 14972658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin modulates both the development and the expression of behavioral sensitization to amphetamine in the rat.
    Wunderlich GR; DeSousa NJ; Vaccarino FJ
    Psychopharmacology (Berl); 2000 Aug; 151(2-3):283-90. PubMed ID: 10972475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.
    Crawley JN; Stivers JA; Blumstein LK; Paul SM
    J Neurosci; 1985 Aug; 5(8):1972-83. PubMed ID: 4040554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype?
    van Kampen J; Stoessl AJ
    Neuropharmacology; 1997; 36(11-12):1679-88. PubMed ID: 9517439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
    Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor selectivity of cholecystokinin effects on mesoaccumbens dopamine neurons.
    Kelland MD; Zhang J; Chiodo LA; Freeman AS
    Synapse; 1991 Jun; 8(2):137-43. PubMed ID: 1882334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice.
    Hirosue Y; Inui A; Miura M; Nakajima M; Okita M; Himori N; Baba S; Kasuga M
    Peptides; 1992; 13(1):155-7. PubMed ID: 1620653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.